ImmUniverse: Advancing Multi-Omics Research and Patient-Centred Innovation
Over the past years, the ImmUniverse project has brought together leading experts from academia, industry, and patient organisations to better understand immune mediated diseases such as ulcerative colitis and atopic dermatitis.
As the project approaches its conclusion, recent discussions among consortium partners highlighted the significant progress achieved and the path forward to maximise long term impact.
Driving Scientific Progress
ImmUniverse has delivered major advances across several areas:
- Integrated multi-omics approaches: By combining genomics, proteomics, metabolomics, and clinical data, the project has enabled a more comprehensive understanding of disease mechanisms and treatment response.
- Biomarker discovery and validation: New candidate biomarkers have been identified to help distinguish responders from non responders and to better monitor disease activity.
- Innovative diagnostic and research technologies: Approaches such as liquid biopsy and tissue microenvironment analysis are opening new possibilities for less invasive and more precise disease monitoring.
- Robust data infrastructure: A secure and interoperable data ecosystem has been established to connect clinical and molecular data, enabling advanced analysis across cohorts
- Deeper biological insights: Multi layer analyses have linked molecular signals to underlying biological processes, including inflammation, immune regulation, and tissue remodeling.
From Data to Long Term Impact
With a large volume of high quality data generated, the focus is now on ensuring that these results continue to create value beyond the project timeline. Key priorities include:
- Finalizing and publishing major scientific outputs
- Enabling continued access to curated datasets
- Defining sustainable data governance and sharing models
- Supporting future research and collaboration
These discussions reflect both the opportunities and challenges of maintaining complex clinical datasets while ensuring compliance and usability
Strengthening Patient Centred Research
Patient involvement has been a key element of the project, with important lessons learned along the way. Consortium partners and patient organisations highlighted the need for:
- Earlier and more continuous patient involvement
- Clear and accessible communication
- Stronger integration of patient perspectives into study design
Building on this, ImmUniverse continues to prioritise outreach activities that make research findings meaningful for patients. A dedicated patient webinar will take place this Wednesday, presenting key insights for people living with atopic eczema and inflammatory bowel disease: https://immuniverse.eu/news/living-with-atopic-eczema-or-ibd-discover-the-latest-research-insights-at-our-immuniverses-patient-meeting
This initiative reflects a commitment to ensuring that scientific progress translates into real world understanding and benefit
Collaboration as a Foundation
The success of ImmUniverse has been built on strong collaboration across disciplines and sectors. Despite challenges, including the COVID 19 pandemic and the complexity of coordinating large scale research, the consortium has maintained momentum and delivered meaningful results
Looking Ahead
As ImmUniverse enters its final phase, the emphasis is on:
- Completing key analyses and publications
- Translating findings into clinical relevance
- Sustaining collaboration and knowledge exchange The project’s legacy will extend beyond its formal end, supporting future research and innovation in immune mediated diseases.
Final Meeting in Milan
As part of this closing phase, consortium partners recently met at Humanitas University in Milan to review progress, align on next steps, and strengthen collaboration. The meeting concluded with a social evening exploring the city through a food tour, offering participants a moment to reflect on the journey and the connections built over the years.
